Monocyte-derived dendritic cells from cirrhotic patients retain similar capacity for maturation/activation and antigen presentation as those from healthy subjects

Cellular Immunology
Shiroh TanoueDavid E Kaplan

Abstract

Few studies have investigated the impact of liver cirrhosis on dendritic cell function. The purpose of this study was to compare the activation and antigen-presentation capacity of monocyte-derived dendritic cells (MoDC) from cirrhotic patients (CIR) relative to healthy donors (HD). MoDC from CIR and HD were matured, phenotyped, irradiated and pulsed with 15mer peptides for two hepatocellular carcinoma-related antigens, alphafetoprotein and glypican-3, then co-cultured with autologous T-cells. Expanded T-cells were evaluated by interferon-gamma ELISPOT and intracellular staining. 15 CIR and 7 HD were studied. While CD14+ monocytes from CIR displayed enhanced M2 polarization, under MoDC-polarizing conditions, we identified no significant difference between HD and CIR in maturation-induced upregulation of co-stimulation markers. Furthermore, no significant differences were observed between CIR and HD in subsequent expansion of tumor antigen-specific IFNγ+ T-cells. MoDCs isolated from cirrhotic individuals retain similar capacity for in vitro activation, maturation and antigen-presentation as those from healthy donors.

References

Mar 22, 2002·The Lancet Oncology·D M Parkin
May 29, 2004·Alcoholism, Clinical and Experimental Research·Gyongyi SzaboPranoti Mandrekar
Oct 9, 2004·Cancer Science·Hiroaki IkedaTakashi Nishimura
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiao-Ying ShangWei-Feng Chen
Mar 18, 2005·Annual Review of Immunology·Tania H Watts
Jul 5, 2005·Journal of Immunological Methods·Marc DauerAndreas Eigler
May 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lisa H ButterfieldJames S Economou
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Angelo SangiovanniMassimo Colombo
May 25, 2007·Cancer Immunology, Immunotherapy : CII·Lisa H ButterfieldJames S Economou
Apr 24, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Aude BonehillKris Thielemans
Nov 5, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel H PalmerDavid H Adams
Jun 16, 2009·Seminars in Immunology·Daphne Y Ma, Edward A Clark
Aug 18, 2009·International Immunology·Songwen JuXueguang Zhang
Oct 13, 2009·Cellular Immunology·P KvistborgM B Zocca
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Dec 17, 2011·International Journal of Clinical Practice·J-H ZhongL-Q Li
Oct 31, 2012·Digestive Diseases·Nathalie SchmidtRobert Thimme
Feb 28, 2013·Human Vaccines & Immunotherapeutics·Daisuke NobuokaTetsuya Nakatsura
Apr 22, 2014·Experimental and Molecular Pathology·Kavindra Kumara WijesunderaJyoji Yamate
Aug 26, 2014·Immunobiology·Ibrahim HatipogluAhmet Tarik Baykal

❮ Previous
Next ❯

Citations

Dec 26, 2015·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shiroh Tanoue, David E Kaplan
Apr 3, 2020·Journal of Hepatology·Christine BernsmeierAxel Périanin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.